RxDoctor Payments DataLook up a doctor →

Altagracia Alcantara Gonzalez, MD

Endocrinology, Diabetes & Metabolism · Bayamon, PRNPI 1376505586

Payments from drug & device makers

$1,001,927in general payments, 2019–2025

Across 420 payments — averaging $2385.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly Export S.A. Puerto Rico Branch$889K
  • Eli Lilly$42K
  • AbbVie$30K
  • Johnson & Johnson$16K
  • Lilly USA, LLC$14K
  • Sanofi-aventis U.S. LLC$6K
  • plus $5K from 12 others
$616,665in research payments, 2019–2025

Across 30 payments — averaging $20,555 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly Export S.A. Puerto Rico Branch$469K
  • Eli Lilly$147K
  • AbbVie$815

What the payments were for

  • Consulting fees$6,05011%
  • Speaking & faculty fees$38,30967%
  • Travel & lodging$5,0159%
  • Food & beverage$8,13014%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,001,927 in reported general payments places this provider in the 95th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

See all endocrinology, diabetes & metabolism providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$14,685
Medicare patients
58
Services billed
217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol753$527,876
OzempicSemaglutide461$462,564
TrulicityDulaglutide293$300,118
JardianceEmpagliflozin327$253,727
SynthroidLevothyroxine Sodium3,604$223,872
MounjaroTirzepatide157$169,022
JanumetSitagliptin Phos/Metformin Hcl173$118,855
Xigduo XrDapaglifloz Propaned/Metformin168$110,505
ProliaDenosumab56$99,407
RybelsusSemaglutide89$94,863
Janumet XrSitagliptin Phos/Metformin Hcl133$94,156
JanuviaSitagliptin Phosphate121$92,832
Synjardy XrEmpagliflozin/Metformin Hcl126$84,658
GlyxambiEmpagliflozin/Linagliptin107$80,268
Trijardy XrEmpaglifloz/Linaglip/Metformin78$62,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi, Trijardy Xr, Tradjenta$286$652,778908 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humalog Mix 75-25, Humulin 70-30$14,156$567,072960 claims
Novo NordiskOzempic, Rybelsus$1,047$557,427550 claims
AstraZenecaFarxiga$988$527,876753 claims
MerckJanumet, Janumet Xr, Januvia$1,517$305,843427 claims
AbbVieSynthroid, Linzess$29,768$242,2353,638 claims
AmgenProlia$177$99,40756 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$6,077$60,738234 claims
Johnson & JohnsonXarelto$16,098$35,46453 claims
BayerKerendia$48$14,59722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

Other endocrinology, diabetes & metabolism in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →